[{"id":"56588e9e-2ec1-4aa9-88e8-86fe7db57c2a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04083066","created_at":"2021-01-18T19:59:32.639Z","updated_at":"2024-07-02T16:36:55.834Z","phase":"Phase 4","brief_title":"Open Randomized Prospective Clinical Study of R-FPD Versus R-MAD Regimen in the Treatment of Primary Central Nervous System Lymphoma","source_id_and_acronym":"NCT04083066","lead_sponsor":"Mingzhi Zhang","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • pemetrexed • Muphoran (fotemustine) • dexamethasone injection"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 09/05/2019","start_date":" 09/05/2019","primary_txt":" Primary completion: 04/01/2023","primary_completion_date":" 04/01/2023","study_txt":" Completion: 04/01/2024","study_completion_date":" 04/01/2024","last_update_posted":"2019-09-10"}]